ZW171 exhibits strong anti-tumor activity in patient derived xenograft (PDX) models of NSCLC and pancreatic cancer, and in ex-vivo patient-derived ovarian cancer organoids with endogenous ...

Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and to induce PD-1 receptor internalization (endocytosis ...

Researchers in Nikolaus Rajewsky's lab at Max Delbrück Center combined high-resolution, single-cell spatial technologies to map a tumor's cellular neighborhoods in 3D and identify potential targets ...

Novocure (NVCR) recognized first non-small cell lung cancer revenues ahead of schedule, with 92 Optune Lua prescriptions for NSCLC received in ...

Taiwan’s health authority on Thursday said it has plans to expand existing National Health Insurance (NHI) coverage to ...

Hong Kong-based biopharma company Akeso (HKEX: 9926) announced that its global first-in-class PD-1/VEGF bispecific antibody, ...

Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as late-brea ...

Seven oral presentations will unveil novel immunotherapy insights, including IBI363, at one of oncology’s biggest global ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual ...